|
SPPL2A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.57524999999659E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.574720E-04 |
| Normal-vs-Stage2 |
3.174400E-04 |
| Normal-vs-Stage3 |
2.04950000000093E-05 |
| Normal-vs-Stage4 |
4.83559999997496E-06 |
| Stage1-vs-Stage2 |
3.726600E-01 |
| Stage1-vs-Stage3 |
1.787650E-01 |
| Stage1-vs-Stage4 |
9.770300E-02 |
| Stage2-vs-Stage3 |
9.258400E-01 |
| Stage2-vs-Stage4 |
5.751200E-01 |
| Stage3-vs-Stage4 |
5.820000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.7117000000485E-06 |
| Normal-vs-AfricanAmerican |
2.876000E-02 |
| Normal-vs-Asian |
5.436300E-03 |
| Caucasian-vs-AfricanAmerican |
3.385600E-01 |
| Caucasian-vs-Asian |
3.412400E-01 |
| AfricanAmerican-vs-Asian |
8.226400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.6342899999966E-05 |
| Normal-vs-Female |
3.77559999999999E-05 |
| Male-vs-Female |
2.692000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.225500E-04 |
| Normal-vs-Age(41-60Yrs) |
1.184399999965E-06 |
| Normal-vs-Age(61-80Yrs) |
3.52770000000557E-05 |
| Normal-vs-Age(81-100Yrs) |
2.289600E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.181700E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.022800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.915400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.667000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.920800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.585800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.742000E-01 |
| Classical-VS-Follicular |
1.093200E-01 |
| Classical-VS-Other |
7.376400E-02 |
| Classical-VS-Normal |
1.408170E-04 |
| Tall-VS-Follicular |
9.444400E-01 |
| Tall-VS-Other |
2.095200E-01 |
| Tall-VS-Normal |
2.628200E-04 |
| Follicular-VS-Other |
3.187000E-01 |
| Follicular-VS-Normal |
1.75749999999919E-05 |
| Other-VS-Normal |
6.027400E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.56846999999072E-05 |
| Normal-vs-N1 |
1.6136199999961E-05 |
| N0-vs-N1 |
4.417600E-01 |
|
|
